Cargando…
Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test
The reference standard for fosfomycin antimicrobial susceptibility testing (AST) is agar dilution, but it is laborious and is not routinely used in diagnostic microbiology. In this study, we evaluated the performance of a ready-to-use commercially available agar dilution kit for fosfomycin AST (Liof...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045359/ https://www.ncbi.nlm.nih.gov/pubmed/35352940 http://dx.doi.org/10.1128/spectrum.02504-21 |
_version_ | 1784695299297509376 |
---|---|
author | Croughs, Peter D. Konijnendijk-de Regt, Michelle Yusuf, Erlangga |
author_facet | Croughs, Peter D. Konijnendijk-de Regt, Michelle Yusuf, Erlangga |
author_sort | Croughs, Peter D. |
collection | PubMed |
description | The reference standard for fosfomycin antimicrobial susceptibility testing (AST) is agar dilution, but it is laborious and is not routinely used in diagnostic microbiology. In this study, we evaluated the performance of a ready-to-use commercially available agar dilution kit for fosfomycin AST (Liofilchem Diagnostics). We compared this kit with the reference standard agar dilution, performed according to the Clinical & Laboratory Standards Institute (CLSI) in 229 clinical isolates. The isolates were selected to represent both Gram-positive and Gram-negative microorganisms, with various MIC values. It consisted of 43 enterococci (E. faecalis n = 16, E. faecium n = 27), 13 methicillin-resistant S. aureus (MRSA), 118 Enterobacterales (Escherichia coli n = 94, Klebsiella pneumoniae n = 20, and Enterobacter cloacae complex n = 4), 55 Pseudomonas aeruginosa, and three ATCC isolates. Using CLSI breakpoints for enterococci for oral treatment of urinary tract infections, European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for intravenous dosing for Enterobacterales and Staphylococci, and epidemiological cutoff value for P. aeruginosa, the essential agreement was 87.5%, and 99.6% after discrepancy resolution. There was no very major error, and 1.9% major error before, and 0.9% major error after resolution of discrepancies. The commercial test showed 100% reproducibility. In conclusion, in comparison to the reference standard, the ready-to-use commercially available agar dilution kit for fosfomycin AST showed excellent performance. IMPORTANCE Fosfomycin is increasingly needed to treat infection due to multidrug resistant microorganisms. Yet, the antimicrobial susceptibility test (AST) of fosfomycin is fraught with difficulties or often laborious to perform. An easy-to-use AST method for fosfomycin is thus needed. In this study, we showed that the ready-to-use commercially available agar dilution kit, in comparison to the reference standard, showed excellent performance. |
format | Online Article Text |
id | pubmed-9045359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-90453592022-04-28 Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test Croughs, Peter D. Konijnendijk-de Regt, Michelle Yusuf, Erlangga Microbiol Spectr Research Article The reference standard for fosfomycin antimicrobial susceptibility testing (AST) is agar dilution, but it is laborious and is not routinely used in diagnostic microbiology. In this study, we evaluated the performance of a ready-to-use commercially available agar dilution kit for fosfomycin AST (Liofilchem Diagnostics). We compared this kit with the reference standard agar dilution, performed according to the Clinical & Laboratory Standards Institute (CLSI) in 229 clinical isolates. The isolates were selected to represent both Gram-positive and Gram-negative microorganisms, with various MIC values. It consisted of 43 enterococci (E. faecalis n = 16, E. faecium n = 27), 13 methicillin-resistant S. aureus (MRSA), 118 Enterobacterales (Escherichia coli n = 94, Klebsiella pneumoniae n = 20, and Enterobacter cloacae complex n = 4), 55 Pseudomonas aeruginosa, and three ATCC isolates. Using CLSI breakpoints for enterococci for oral treatment of urinary tract infections, European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for intravenous dosing for Enterobacterales and Staphylococci, and epidemiological cutoff value for P. aeruginosa, the essential agreement was 87.5%, and 99.6% after discrepancy resolution. There was no very major error, and 1.9% major error before, and 0.9% major error after resolution of discrepancies. The commercial test showed 100% reproducibility. In conclusion, in comparison to the reference standard, the ready-to-use commercially available agar dilution kit for fosfomycin AST showed excellent performance. IMPORTANCE Fosfomycin is increasingly needed to treat infection due to multidrug resistant microorganisms. Yet, the antimicrobial susceptibility test (AST) of fosfomycin is fraught with difficulties or often laborious to perform. An easy-to-use AST method for fosfomycin is thus needed. In this study, we showed that the ready-to-use commercially available agar dilution kit, in comparison to the reference standard, showed excellent performance. American Society for Microbiology 2022-03-30 /pmc/articles/PMC9045359/ /pubmed/35352940 http://dx.doi.org/10.1128/spectrum.02504-21 Text en Copyright © 2022 Croughs et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Croughs, Peter D. Konijnendijk-de Regt, Michelle Yusuf, Erlangga Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test |
title | Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test |
title_full | Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test |
title_fullStr | Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test |
title_full_unstemmed | Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test |
title_short | Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test |
title_sort | fosfomycin susceptibility testing using commercial agar dilution test |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045359/ https://www.ncbi.nlm.nih.gov/pubmed/35352940 http://dx.doi.org/10.1128/spectrum.02504-21 |
work_keys_str_mv | AT croughspeterd fosfomycinsusceptibilitytestingusingcommercialagardilutiontest AT konijnendijkderegtmichelle fosfomycinsusceptibilitytestingusingcommercialagardilutiontest AT yusuferlangga fosfomycinsusceptibilitytestingusingcommercialagardilutiontest |